What is the difference between ARA-290 and Glutathione?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Glutathione: Master endogenous antioxidant tripeptide; neutralizes ROS, regenerates vitamins C and E, supports phase II liver detoxification, maintains intracellular redox balance

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Glutathione FDA approved?

Glutathione is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Glutathione administered in research settings?

In research settings, Glutathione is typically administered via the intravenous, subcutaneous, oral (liposomal), nebulized, or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Glutathione

Peptide Comparison

ARA-290 vs Glutathione

Name: ARA-290 vs Glutathione — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

Glutathione

gamma-glutamylcysteinylglycine

RecoveryNot EvaluatedCompoundable

Half-life: Variable (~2-5 minutes IV; hours liposomal)

136 providers listed

Full Glutathione profile →

Bottom line

ARA-290 has a longer half-life than Glutathione, so it generally needs less frequent dosing.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Glutathione

Half-life

Variable (~2-5 minutes IV; hours liposomal)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Less frequent dosing (longer half-life)	ARA-290
Oral administration option	Glutathione
Lower typical price per mg	Glutathione
More provider options (17 vs 136)	Glutathione

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Glutathione

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

Variable (~2-5 minutes IV; hours liposomal)

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

intravenous, subcutaneous, oral (liposomal), nebulized, oral

Availability

Research Only

Compoundable

Providers

17 listed

136 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

On FDA 503A Category 1 bulk drug substances list for injectable/IV compounding. Also sold as dietary supplement. Not FDA-approved as standalone drug. Compoundable by licensed 503A pharmacies.

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

Glutathione

RCT · 1 key study · dated evidence base — most recent 2009

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

Glutathione

RCT2009 · Movement Disorders

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Glutathione

Master endogenous antioxidant tripeptide; neutralizes ROS, regenerates vitamins C and E, supports phase II liver detoxification, maintains intracellular redox balance

Research Areas

intracellular redox homeostasis and ROS scavengingIV administration bypasses oral bioavailability failure — acute plasma GSH elevationmelanin synthesis modulation studied for skin pigmentation (mixed evidence)glutathione peroxidase substrate — core detoxification pathway cofactor

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Glutathione

Reported (Unverified — Pending Clinical Review)

asthma (nebulized form)

No established clinical contraindications

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

Glutathione

$0.04/mg

$0.03 – $0.09 range

10 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

Glutathione

136 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Glutathione — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ara-290/glutathione

https://peptidebase.io/peptides/compare/ara-290/glutathione Methodology License Download JSON Download CSV